Complete Filing Data
CASI Pharmaceuticals, Inc. reported Stockholders Equity of $1.85 million for FY2024.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean CASI Pharmaceuticals, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Net Income * | -$39.3M | -$27.0M | -$41.0M | -$36.7M | -$48.3M |
| Revenue * | $28.5M | $33.9M | $38.0M | $30.0M | $15.0M |
| Selling And Marketing Expense | $17.9M | $16.5M | $14.3M | $14.7M | $7.8M |
| Other Nonoperating Income Expense | $188.0K | $764.0K | $44.0K | $558.0K | $82.0K |
| Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax | $574.0K | $497.0K | $2.7M | -$1.4M | -$3.3M |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -$574.0K | -$1.1M | -$4.5M | $2.0M | $3.9M |
| Operating Income Loss | -$39.6M | -$25.1M | -$34.0M | -$41.5M | -$52.8M |
| Income Tax Expense Benefit | $0.00 | -$81.0K | $2.0M | $0.00 | $0.00 |
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | -$38.1M | -$26.3M | -$37.4M | -$35.8M | -$47.5M |
| Income Loss From Continuing Operations Before Equity Method Investments Noncontrolling Interest After Tax | -$38.1M | -$26.2M | -$39.4M | -$35.8M | -$47.5M |
| Gross Profit | $11.1M | $20.1M | $27.3M | $17.6M | $5.6M |
| General And Administrative Expense | $23.6M | $25.4M | $23.4M | $23.7M | $19.7M |
| Cost Of Goods And Services Sold | $17.4M | $13.8M | $15.8M | $12.6M | $9.5M |
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$39.8M | -$27.4M | -$44.8M | -$33.9M | -$43.6M |
| Comprehensive Income Net Of Tax | -$39.8M | -$24.2M | -$34.2M | -$33.8M | -$43.3M |
| Amortization Of Intangible Assets And Held For Sale | $1.1M | $1.3M | $1.2M | $1.3M | $1.4M |
| Net Income Loss Attributable To Redeemable Noncontrolling Interest | -$2.6M | -$8.7M | -$700.0K | -$918.0K | |
| Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | -$3.2M | -$10.6M | -$88.0K | -$331.0K | |
| Research And Development Expense Excluding Acquired In Process Cost | $9.9M | $16.0M | $14.4M | $11.5M | |
| Interest Income Expense Net | $614.0K | $127.0K | $321.0K | $866.0K | |
| Income Loss From Equity Method Investments | -$1.2M | -$48.0K | -$846.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Stockholders Equity | $1.9M | $24.2M | $44.6M | $84.5M | $81.5M | $73.0M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $13.5M | $17.1M | $47.1M | $38.7M | $57.1M | $53.6M |
| Reduction In Carrying Amount Of Right Of Use Assets | $1.1M | $988.0K | $1.2M | $1.3M | $1.3M | |
| Operating Lease Lease Income | $0.00 | $0.00 | $60.0K | $148.0K | $140.0K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$3.6M | -$30.0M | $8.4M | -$18.4M | $3.4M | |
| Gain Loss On Disposition Of Intangible Assets | $479.0K | -$2.1M | -$65.0K | $1.2M | ||
| Gain Loss On Disposition Of Assets1 | $479.0K | -$2.1M | -$65.0K | $1.2M | ||
| Treasury Stock Value | $9.6M | $9.6M | $9.3M | $8.0M | ||
| Treasury Stock Common Shares | 412.0K | 412.0K | 275.8K | 8.0K | ||
| Retained Earnings Accumulated Deficit | -$700.1M | -$660.8M | -$637.2M | -$605.6M | ||
| Property Plant And Equipment Net | $7.9M | $9.2M | $11.8M | $12.7M | ||
| Prepaid Expense And Other Assets Current | $2.9M | $2.6M | $3.0M | $1.7M | ||
| Other Liabilities Noncurrent | $15.4M | $15.5M | $12.3M | $14.3M | ||
| Other Assets Noncurrent | $587.0K | $766.0K | $1.1M | $2.2M | ||
| Operating Lease Right Of Use Asset | $3.5M | $2.4M | $1.4M | $9.1M | ||
| Long Term Investments | $1.9M | $1.7M | $4.4M | $40.1M | ||
| Liabilities Current | $36.5M | $16.7M | $17.0M | $13.2M | ||
| Liabilities And Stockholders Equity | $53.7M | $75.3M | $96.2M | $138.3M | ||
| Liabilities | $51.8M | $51.1M | $29.3M | $30.3M | ||
| Inventory Net | $5.3M | $15.9M | $6.1M | $1.9M | ||
| Intangible Assets Net Excluding Goodwill | $238.0K | $1.8M | $1.1M | $12.2M | ||
| Equity Securities Fv Ni Unrealized Gain Loss | -$581.0K | -$8.9M | $5.7M | $4.3M | ||
| Common Stock Value | $2.0K | $1.0K | $1.0K | $1.0K | ||
| Cash And Cash Equivalents At Carrying Value | $13.5M | $17.1M | $47.1M | $38.7M | ||
| Assets Current | $39.6M | $59.3M | $73.4M | $62.0M | ||
| Assets | $53.7M | $75.3M | $96.2M | $138.3M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$1.8M | -$1.2M | -$703.0K | $2.0M | ||
| Accounts Receivable Net Current | $15.3M | $9.6M | $13.0M | $9.8M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Share Based Compensation | $1.3M | $7.2M | $7.0M | $7.8M | $7.8M |
| Payments To Acquire Property Plant And Equipment | $223.0K | $204.0K | $5.6M | $8.9M | $1.5M |
| Net Cash Provided By Used In Operating Activities | -$29.2M | -$20.0M | -$21.1M | -$26.8M | -$25.9M |
| Net Cash Provided By Used In Investing Activities | $11.2M | -$9.7M | $31.2M | -$20.7M | -$20.7M |
| Net Cash Provided By Used In Financing Activities | $15.4M | -$907.0K | -$3.3M | $29.6M | $47.2M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$319.0K | -$701.0K | $1.4M | $1.3M | $184.0K |
| Increase Decrease In Inventories | -$5.8M | $9.7M | $4.2M | $551.0K | -$3.2M |
| Increase Decrease In Accrued Liabilities | $1.5M | -$876.0K | -$912.0K | $2.3M | -$1.4M |
| Increase Decrease In Accounts Receivable | $5.8M | -$3.4M | $3.2M | $5.2M | $3.4M |
| Increase Decrease In Accounts Payable Trade | -$1.7M | $1.1M | $1.1M | $1.5M | -$1.5M |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -$1.1M | $518.0K | $1.6M | -$469.0K | $2.9M |
| Proceeds From Sale Of Property Plant And Equipment | $0.00 | $138.0K | $10.0K | $0.00 | |
| Proceeds From Lines Of Credit | $4.0M | $709.0K | $783.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 250.0M | |
| Weighted Average Number Of Shares Outstanding Basic | 15.3M | 13.4M | 13.6M | 13.6M | 11.0M |
| Weighted Average Number Of Diluted Shares Outstanding | 15.3M | 13.4M | 13.6M | 13.6M | 11.0M |
| Earnings Per Share Diluted | $-2.56 | $-2.02 | $-3.01 | $-2.69 | $-4.37 |
| Earnings Per Share Basic | $-2.56 | $-2.02 | $-3.01 | $-2.69 | $-4.37 |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Outstanding | 15.5M | 13.4M | 13.5M | 14.0M | |
| Common Stock Shares Issued | 15.9M | 13.8M | 13.7M | 14.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Foreign Currency Transaction Gain Loss Before Tax | -$192.0K | $200.0K | $3.2M | $321.0K | -$1.3M |
| Costs And Expenses | $50.8M | $45.1M | $61.3M | $59.1M | $58.4M |
| Capital Expenditures Incurred But Not Yet Paid | $8.0K | $99.0K | $44.0K | $3.3M | $467.0K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $1.3M | $7.2M | $7.0M | $7.8M | $7.8M |
| Stock Repurchased And Retired During Period Value | $278.0K | $3.3M | |||
| Redeemable Noncontrolling Interest Accretion To Redemption Value Adjustment | $3.3M | $9.5M | $1.5M | $1.7M | |
| Depreciation And Amortization | $2.5M | $1.2M | $468.0K | $562.0K | |
| Additional Paid In Capital | $713.3M | $695.8M | $691.8M | $696.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2022 |
|---|---|
| Foreign Currency Transaction Gain Loss Before Tax | |
| Costs And Expenses | |
| Capital Expenditures Incurred But Not Yet Paid | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | |
| Stock Repurchased And Retired During Period Value | $3.0M |
| Redeemable Noncontrolling Interest Accretion To Redemption Value Adjustment | |
| Depreciation And Amortization | |
| Additional Paid In Capital |
Most recent annual filing with the SEC: March 31, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.